3. Histological subtype of high-grade serous carcinoma or high-grade endometrioid adenocarcinoma.
4. Received only prior first-line platinum-based chemotherapy and achieved complete response (CR) or partial response (PR) to chemotherapy.
5. Patients who received niraparib maintenance therapy in clinical practice.
You may not be if
1. Patients with comorbidities that, in the investigator's judgment, would seriously endanger patient safety or interfere with medication administration.
2. Patients receiving anti-tumor drugs for other concurrent malignant neoplasms.
3. Pregnant or breastfeeding patients.
Clareo Health | Real-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian Cancer
